SARS-CoV-2-specific Humoral Immune Responses after A Single dose of Inactivated Whole-virus SARS-CoV-2 Vaccine in Kidney Transplant Recipients: An Initial Report

Jackrapong Bruminhent, MD^{1,2}, Sarinya Boongird, MD^{2,3}, Montira Assanatham, MD^{2,3}, Sasisopin Kiertiburanakul, MD, MHS¹, Kumthorn Malathum, MD¹, Arkom Nongnuch, MD^{2,3}, Angsana Phuphuakrat, MD, PhD¹, Pongsathon Chaumdee, MD⁴, Sopon Jirasiritham, MD^{2,5,6}, Chitimaporn Janphram, MD⁷, Sansanee Tossiri, MD⁷, Supparat Upama, MD⁸, Chavachol Sethaudom^{9,*}

¹Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

²Excellence Center of Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

³Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

⁴Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

⁵Division of Vascular and Transplant Surgery, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

⁶Praram 9 Hospital, Bangkok, Thailand

⁷Somdech Phra Debaratana Medical Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

⁸Samitivej Hospital Sukhumvit, Bangkok, Thailand

⁹Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand

***Correspondence**

Chavachol Sethaudom

chavachol@hotmail.com

Abstract

We presented an initial pilot study report focused on immunogenicity and safety following an inactivated whole-virus severe acute respiratory syndrome coronavirus 2 vaccination among kidney transplant (KT) recipients. At four weeks after the first dose of vaccine, the level of anti-receptor-binding domain IgG antibody was not significantly different compared to before vaccination in 30 KT recipients ($p = 0.45$). Moreover, a significant lower mean (95% CI) anti-receptor-binding domain IgG antibody was observed compared to 30 immunocompetent controls (2.4 [95% CI 1.3-3.5] vs. 173.1 [95% CI 88.3-2,457.9] AU/mL, $p < 0.001$). Mild adverse events included fever (17%) and localized pain at the injection site (14%) were observed after vaccination.

Brief report

Solid-organ transplant (SOT) recipients are at greater risk of significant coronavirus disease 2019 (COVID-19) related morbidity and mortality.¹ Immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered one of the most promising strategies to alleviate unfavorable consequences among SOT recipients and their allograft.

Several platforms of the SARS-CoV-2 vaccine were developed and utilized variably worldwide among immunocompetent individuals. Data on SARS-CoV-2-specific immune

responses among patients with immunocompromised states such as those receiving SOT has been scarce. Few recent studies evaluated the immunogenicity of SARS-CoV-2 messenger RNA vaccine in SOT recipients receiving immunosuppressant revealed an acceptable safety profile. However, a significant proportion of recipients who developed suboptimal immunologic response after a single and double dose of the vaccine is a concern (17% and 54%, respectively).^{2,3,4} On the other hand, immunogenicity, and safety following immunization with an inactivated whole-virus SARS-CoV-2 vaccine among SOT recipients have not been assessed.⁵

A pilot, multi-center, prospective study of adult Asian KT recipients who received a 4-week interval immunization of an inactivated whole-virus SARS-CoV-2 vaccine, CoronaVac[®] (Sinovac Biotech Ltd.) was conducted from April 2021 to June 2021. SARS-CoV-2-specific humoral immunity was measured before, one month after the first dose, using a quantitative assay of SARS-CoV-2 immunoglobulin G (IgG) assay (Abbott diagnostics) that tests for antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, which reported in arbitrary units (AU)/mL. Those were also referenced to immunocompetent patients. The study was approved by the Institutional Review Board of the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (MURA2021/242). All patients provided written informed consent prior to participation.

A total of adult 60 patients was recruited into the study and comprised of immunocompetent patients (n=30) and KT recipients (n=30). Among KT recipients, the median age was 47 years (interquartile range [IQR], 41-52 years), and 67% of them were men. The median time since transplant was 3.6 years (IQR, 2-9.5 years). The maintenance immunosuppression regimen included tacrolimus (57%), cyclosporine (29%), corticosteroids (97%), mycophenolic acid (91%), sirolimus (3%), and everolimus (3%). At four weeks after the

first dose of vaccine, a mean (95% confidence interval [CI]) of anti-receptor-binding domain IgG antibody was not significantly different compared to before vaccination in all participants ($p = 0.45$) **Figure 1.** KT recipients developed significantly lower anti-receptor-binding domain IgG antibody compared to immunocompetent patients (2.4 [95% CI 1.3-3.5] vs. 173.1 [95% CI 88.3-2,457.9] AU/mL, $p < 0.001$). Approximately half of the participants did not report any adverse events (AEs) followed by mild AEs such as fever (17%) and pain at the injection site (14%). No serious AEs observed.

Our initial report revealed that KT recipients receiving the first dose of an inactivated whole-virus SARS-CoV-2 vaccine could remain vulnerable to infection, however, with infrequent and mild adverse reactions. A complete result is ongoing, and further large-scale studies reaffirmed this result is needed (Thai Clinical Trials Registry, TCTR20210226002).

Disclosure

The authors of this manuscript have no conflicts of interest to disclose

Funding

This study was granted by the National Research Council of Thailand (102912).

References

1. Hadi YB, Naqvi SF, Kupec JT, Sofka S, Sarwari A. Outcomes of Coronavirus Infectious Disease -19 (COVID-19) in Solid Organ Transplant Recipients: A Propensity Matched Analysis of a Large Research Network. Transplantation. 2021 Feb 5.

2. Marion O, Del Bello A, Abravanel F, Couat C, Faguer S, Esposito L, Hebral AL, Izopet J, Kamar N. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. *Ann Intern Med*. 2021 May 25.
3. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*. 2021 May 4;325(17):1784-1786.
4. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA*. 2021 May 5:e217489.
5. Baraniuk C. What do we know about China's covid-19 vaccines? *BMJ*. 2021 Apr 9;373:n912.

Figure legend

Figure 1 A mean with 95% confidence interval of anti-receptor-binding domain immunoglobulin G antibody in immunocompetent patients and kidney transplant recipients before and at four weeks after a single dose of inactivated whole-virus SARS-CoV-2 vaccine.